Investment Firm
Overview
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Feb 25, 2019
Series B
Highlights
Location
Social
Participant Investors
3
Investor Name |
---|
Kington Capital |
Temasek Holdings |
Lilly Asia Ventures |
Gracell Biotechnologies raised $85000000 on 2019-02-25 in Series B
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Company Funding History
4
Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
---|---|---|---|---|
Feb 25, 2019 | Series B - Gracell Biotechnologies | 5 | - | 85.0M |
Jan 01, 2018 | Series A - Gracell Biotechnologies | 1 | - | undefined |
Oct 28, 2020 | Series C - Gracell Biotechnologies | 7 | - | 100.0M |
Aug 07, 2023 | Post-IPO Equity - Gracell Biotechnologies | 9 | - | 100.0M |
Recent Activity
There is no recent news or activity for this profile.